SCHEMBL2503036

SCHEMBL2503036

CC(=O)c1ccc(CO[Si](C)(C)C(C)(C)C)cc1OC(F)F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
PKM P14618 1/20 0.36
ALDH1A1 P00352 4/20 0.36
MAOB P27338 5/20 0.34
MAOA P21397 3/20 0.34
HCRTR1 O43613 1/20 0.33
HCRTR2 O43614 1/20 0.33
USP14 P54578 1/20 0.33
MAPT P10636 2/20 0.33
PDE4D Q08499 1/20 0.33
BACE1 P56817 1/20 0.33
HTT P42858 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
LMNA P02545 2/20 0.32
RAB9A P51151 2/20 0.32
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18310146 0.85 DRD2 (0.41) MEN1KMT2AALDH1A1MAPTHTT
SCHEMBL2502276 0.79 PLK1 (0.33) MEN1KMT2AUSP14HTTLMNA
SCHEMBL2494564 0.79 PLK1 (0.33) MEN1KMT2AUSP14HTTLMNA
SCHEMBL19837265 0.74 MEN1 (0.44) MEN1KMT2APKMALDH1A1MAPT
SCHEMBL8128802 0.73 KDM4E (0.44) MEN1KMT2AALDH1A1MAPTHTT
SCHEMBL16146667 0.73 PARP15 (0.46) MEN1KMT2AALDH1A1MAPTHTT
SCHEMBL2853361 0.73 ALDH1A1 (0.38) PKMALDH1A1USP14BACE1L3MBTL1
SCHEMBL18149330 0.72 POLB (0.36) MEN1KMT2AMAPTPDE4DBACE1
SCHEMBL1390757 0.72 ALDH1A1 (0.43) MEN1KMT2AALDH1A1MAOBMAOA
SCHEMBL14648434 0.71 KMT2A (0.48) KMT2AALDH1A1MAOBMAOAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1813613-B1 NOVEL FUSED IMIDAZOLE DERIVATIVE MSD KK (JP) 2012-12-19 EP disclosed
US-8030327-B2 3-[1-(2-chlorophenyl)ethoxy]-5-imidazo[1,2-a]pyridin-3-ylthiophene-2-carboxyamide; polo like kinase inhibitor; antitumor and anticarcinogenic agent; mitotic phase (M phase) of the cell cycle MDS K.K. (JP) 2011-10-04 US disclosed
US-20080103136-A1 Novel Fused Imidazole Derivative MSD K.K. (JP) 2008-05-01 US disclosed
EP-1813613-A1 NOVEL FUSED IMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103136-A1 Novel Fused Imidazole Derivative HRH4, H1-4, H1-3 MEN1 1505/4885KMT2A 1819/4885PKM 3607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.